RobinTZonMD

Medical Director of Oncology Research at Memorial Hospital and NCI CCOP Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium,

Join to view full profile

Dr. Zon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Zon's full profile

Already have an account?

Office
5340 Holy Cross Pkwy
Mishawaka, IN 46545
Phone+1 800-860-8100

Fax+1 574-282-2813
Is this information wrong?

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
St Vincent Hospital and Health Care CenterResidency, Internal Medicine, 1992 - 1995
Indiana University School of MedicineClass of 1992

Certifications & Licensure

IN State Medical License 1993 - 2025
OH State Medical License 2022 - 2024
MI State Medical License 2009 - 2014
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2004

Clinical Trials

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2002 Jan 29
Completed
Phase 3
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 3
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer Start of enrollment: 2008 Jul 30
Completed
Phase 2
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2010 Jan 01
Terminated
Phase 2
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Start of enrollment: 2012 Jun 15
Completed
Phase 2
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 01
Completed
Phase 3
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 May 01
Terminated
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Patient Experiences, Trust, and Preferences for Health Data Sharing.
Rochelle D. Jones, Chris Krenz, Kent A. Griffith, Rebecca Spence, Angela R. Bradbury, Raymond De Vries, Sarah T. Hawley, Robin Zon, Sage Bolte, Navid Sadeghi, Richard ...> ;JCO Oncology Practice. 2021 Dec 2
48 citations
Telehealth in Oncology: ASCO Standards and Practice Recommendations
Robin Zon, Erin B. Kennedy, Kerin B. Adelson, Sibel Blau, Natalie R. Dickson, David Gill, Nicole Laferriere, Ana Maria Lopez, Therese M. Mulvey, Debra A. Patt, Todd A....> ;JCO Oncology Practice. 2021 Jul 28
59 citations
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
Nathan A. Pennell, Melissa S. Dillmon, Laura A. Levit, E. Allyn Moushey, Ajjai Alva, Sibel Blau, Timothy L. Cannon, Natalie R. Dickson, Maximilian Diehn, Mithat Gonen,...> ;Journal of Clinical Oncology. 2021 Jan 10
5 citations
Governance of a Learning Health Care System for Oncology: Patient Recommendations.
Rochelle D. Jones, Chris Krenz, Kent A. Griffith, Rebecca Spence, Angela R. Bradbury, Raymond De Vries, Sarah T. Hawley, Robin Zon, Sage Bolte, Navid Sadeghi, Richard ...> ;JCO Oncology Practice. 2020 Oct 23
78 citations
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer ...
Greg Andrew Durm, Salma K. Jabbour, Sandra Althouse, Ziyue Liu, Ahad Ali Sadiq, Robin Zon, Shadia I. Jalal, Goetz H. Kloecker, Michael J. Williamson, Karen L. Reckamp,...> ;Cancer. 2020 Oct 1
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-...
Roberto A. Leon-Ferre, Edith A. Perez, David W. Hillman, Celyne Bueno, Alejandra T. Perez, Beiyun Chen, Robert B. Jenkins, Donald W. Northfelt, David B. Johnson, Rober...> ;Breast Cancer Research and Treatment. 2020 Aug 1
6 citations
Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology.
Rochelle D. Jones, Chris Krenz, Michele C. Gornick, Kent A. Griffith, Rebecca Spence, Angela R. Bradbury, Raymond De Vries, Sarah T. Hawley, Rodney A. Hayward, Robin Z...> ;JCO Oncology Practice. 2020 Apr 30
15 citations
Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology
Reshma Jagsi, Kent A. Griffith, Rochelle D. Jones, Chris Krenz, Michele C. Gornick, Rebecca Spence, Raymond De Vries, Sarah T. Hawley, Robin Zon, Sage Bolte, Navid Sad...> ;Journal of Clinical Oncology. 2019 Oct 2
ASCO Standards for Safe Handling of Hazardous Drugs.
Paul Celano, Erin B. Kennedy, Thomas K. Oliver, Robin Zon> ;Journal of Oncology Practice. 2019 Jan 22
Safe Handling of Hazardous Drugs: ASCO Standards Summary.
Paul Celano, Erin B. Kennedy, Robin Zon> ;Journal of Oncology Practice. 2019 Jan 9
13 citations
Safe Handling of Hazardous Drugs: ASCO Standards
Paul Celano, Christopher A. Fausel, Erin B. Kennedy, Tim M. Miller, Thomas K. Oliver, Ray D. Page, Jeffery C. Ward, Robin Zon> ;Journal of Clinical Oncology. 2019 Jan 8
1 citations
Reply to S.D. Lucio.
Gary H. Lyman, Robin Zon, R. Donald Harvey, Richard L. Schilsky> ;Journal of Clinical Oncology. 2018 May 30
4 citations
Rationale, Opportunities, and Reality of Biosimilar Medications.
Gary H Lyman, Robin Zon, R Donald Harvey, Richard L Schilsky> ;The New England Journal of Medicine. 2018 May 24
70 citations
American Society of Clinical Oncology Statement: Biosimilars in Oncology
Gary H. Lyman, Edward P. Balaban, Michael Diaz, Andrea Ferris, Anne Tsao, Emile E. Voest, Robin Zon, Michael Francisco, Sybil Green, Shimere Sherwood, R. Donald Harvey...> ;Journal of Clinical Oncology. 2018 Feb 14
25 citations
Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.
Bobby Daly, Robin Zon, Ray D. Page, Stephen B. Edge, Gary H. Lyman, Sybil R. Green, Dana S. Wollins, Linda D. Bosserman> ;Journal of Oncology Practice. 2018 Feb 7
1 citations
When Investment Meets Return
Robin Zon, Ray D. Page> ;Journal of Oncology Practice. 2018 Feb 7
32 citations
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gen...
Michaela Tsai, Shelly S. Lo, William Audeh, Rubina Qamar, Raye Budway, Ellis G. Levine, Pat Whitworth, B Mavromatis, Robin Zon, Dwight Oldham, Sarah Untch, Tina Treece...> ;JAMA Oncology. 2018 Jan 11
2 citations
Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
Shadia I. Jalal, Nasser H. Hanna, Robin Zon, Gregory A. Masters, Hossein Borghaei, Karuna Koneru, Sunil Badve, Nagendra K A Prasad, Neeta Somaiah, Jingwei Wu, Zhangshe...> ;American Journal of Clinical Oncology. 2017 Aug 1
1 citations
USP3: United in Safeguarding Patients, Personnel, and Providers
Robin Zon> ;Journal of Oncology Practice. 2017 Feb 21
6 citations
Summary of the Workshop on the Safe Handling of Hazardous Drugs Cohosted by the National Institute for Occupational Safety and Health and the American Society of Clini...
Thomas H. Connor, Paul Celano, James N. Frame, Robin Zon> ;Journal of Oncology Practice. 2017 Feb 21
23 citations
American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology
Robin Zon, Stephen B. Edge, Ray D. Page, James N. Frame, Gary H. Lyman, James L. Omel, Dana S. Wollins, Sybil R. Green, Linda D. Bosserman> ;Journal of Oncology Practice. 2017 Feb 7
8 citations
Perspectives on the Use of Clinical Pathways in Oncology Care.
Anne C. Chiang, Peter Ellis, Robin Zon> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2017 Jan 1
51 citations
American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology
Robin Zon, James N. Frame, Michael N. Neuss, Ray D. Page, Dana S. Wollins, Steven K. Stranne, Linda D. Bosserman> ;Journal of Oncology Practice. 2016 Jan 12
6 citations
Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community.
Eileen P. Dimond, Robin Zon, Bryan J. Weiner, Diane St. Germain, Andrea M. Denicoff, Kandie Dempsey, Angela C. Carrigan, Randall Teal, Marjorie J. Good, Worta McCaskil...> ;Journal of Oncology Practice. 2016 Jan 1
4 citations
Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106.
Kathryn M. Greven, L.D. Case, Lawrence Nycum, Patricia Zekan, David D. Hurd, Ernie P. Balcueva, Glenn Mills, Robin Zon, Patrick J. Flynn, David D. Biggs, Edward G. Sha...> ;The Journal of Community and Supportive Oncology. 2015 Mar 1
Join now to see all

Lectures

Pathways and MACRA: ASCO’s Proposal
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 TermDecember 19th, 2022
Most Community Physicians Say Clinical Pathways Improve CareNovember 11th, 2021
Steroid Dose and TaxanesOctober 10th, 2021
Join now to see all